GATA1 and transient myeloproliferative syndrome: However, features identified as being predictive of progression include the persistence of immunophenotypic TMD blasts (>0.1%) or detection of GATA1 mutations by quantitative PCR using patient-specific oligonucleotides at week 12 and the presence of pleural effusions at diagnosis of TMD [19, 21].